BR112018016734A2 - peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres - Google Patents
peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceresInfo
- Publication number
- BR112018016734A2 BR112018016734A2 BR112018016734A BR112018016734A BR112018016734A2 BR 112018016734 A2 BR112018016734 A2 BR 112018016734A2 BR 112018016734 A BR112018016734 A BR 112018016734A BR 112018016734 A BR112018016734 A BR 112018016734A BR 112018016734 A2 BR112018016734 A2 BR 112018016734A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- cells
- relates
- cancers
- present
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/836—Intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/844—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/868—Vaccine for a specifically defined cancer kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302010P | 2016-03-01 | 2016-03-01 | |
| GBGB1603568.5A GB201603568D0 (en) | 2016-03-01 | 2016-03-01 | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| PCT/EP2017/054559 WO2017148888A1 (en) | 2016-03-01 | 2017-02-28 | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018016734A2 true BR112018016734A2 (pt) | 2018-12-26 |
Family
ID=55807140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018016734A BR112018016734A2 (pt) | 2016-03-01 | 2017-02-28 | peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10400011B2 (enExample) |
| EP (2) | EP3423085A1 (enExample) |
| JP (2) | JP2019516663A (enExample) |
| KR (1) | KR20180118702A (enExample) |
| CN (1) | CN109152825A (enExample) |
| AU (2) | AU2017227967B2 (enExample) |
| BR (1) | BR112018016734A2 (enExample) |
| CA (1) | CA3014848A1 (enExample) |
| CO (1) | CO2018008763A2 (enExample) |
| CR (4) | CR20180398A (enExample) |
| EA (1) | EA201891670A1 (enExample) |
| GB (1) | GB201603568D0 (enExample) |
| IL (1) | IL261266B2 (enExample) |
| MA (2) | MA43090A1 (enExample) |
| MX (1) | MX2018010167A (enExample) |
| SG (3) | SG10202110228YA (enExample) |
| TW (1) | TWI641617B (enExample) |
| WO (1) | WO2017148888A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302705A (en) | 2016-03-01 | 2023-07-01 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides, and cell-based medicaments for use in immunotherapy against urinary bladder cancer and other cancers |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| AU2017386682A1 (en) | 2016-12-28 | 2019-07-25 | Invvax, Inc. | Influenza vaccines |
| CA3058807A1 (en) | 2017-04-03 | 2018-10-11 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
| LT3652215T (lt) | 2017-07-14 | 2021-05-25 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| CA3083242A1 (en) * | 2017-11-21 | 2019-05-31 | Naofumi MIWA | Human cancer cell metastasis inhibitory agent and human cancer cell determination agent |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| CN111684062A (zh) | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | 制造t细胞的方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| WO2019204683A1 (en) | 2018-04-19 | 2019-10-24 | Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
| TW202015719A (zh) | 2018-06-19 | 2020-05-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| CN113538407B (zh) | 2018-12-29 | 2022-10-14 | 北京市商汤科技开发有限公司 | 锚点确定方法及装置、电子设备和存储介质 |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| ES2991645T3 (es) | 2019-06-06 | 2024-12-04 | Immatics Biotechnologies Gmbh | Clasificación con contraselección mediante péptidos de secuencia similar |
| EP3982980A4 (en) * | 2019-06-12 | 2023-11-29 | BioNTech US Inc. | NEOANTIGEN COMPOSITIONS AND USES THEREOF |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CN111118011B (zh) * | 2020-02-11 | 2022-09-06 | 昆明医科大学 | 一种抑制hsa_circ_0027478表达的siRNA及其应用 |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CN115975943A (zh) * | 2020-07-14 | 2023-04-18 | 广州泛恩生物科技有限公司 | 基于acp5阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用 |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| MX2023012899A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Polipeptidos de union a antigeno bma031 mejorados. |
| WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| US12319720B2 (en) * | 2021-08-31 | 2025-06-03 | Washington University | Neoantigen vaccines for triple negative breast cancer |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115785206B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标07及其用途 |
| CN115961032A (zh) * | 2022-09-19 | 2023-04-14 | 深圳市罗湖区人民医院 | 一种膀胱癌相关突变基因的检测探针、检测试剂盒、突变质控品 |
| WO2025021979A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| WO2025021968A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Antigen binding proteins against mageb2 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2444691A1 (en) * | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| WO2003104429A2 (en) | 2002-06-10 | 2003-12-18 | Idec Pharmaceuticals Corporation | Genes overexpressed by ovarian cancer and their use in developing novel therapeutics |
| ES2341802T3 (es) * | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| KR100906145B1 (ko) * | 2006-05-30 | 2009-07-03 | 한국생명공학연구원 | Ｔｍｐｒｓｓ4 억제제를 유효성분으로 포함하는 항암제 |
| EP2402437B1 (en) * | 2006-07-05 | 2016-06-01 | Catalyst Biosciences, Inc. | Protease screening methods and proteases identified thereby |
| DK2172211T3 (en) * | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| TW201124530A (en) * | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| EP2336771A1 (en) * | 2009-12-16 | 2011-06-22 | Universität Duisburg-Essen | HAS3v2 as tumor marker |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201511792D0 (en) * | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
-
2016
- 2016-03-01 GB GBGB1603568.5A patent/GB201603568D0/en not_active Ceased
-
2017
- 2017-02-28 CR CR20180398A patent/CR20180398A/es unknown
- 2017-02-28 MA MA43090A patent/MA43090A1/fr unknown
- 2017-02-28 BR BR112018016734A patent/BR112018016734A2/pt not_active Application Discontinuation
- 2017-02-28 EP EP17707843.3A patent/EP3423085A1/en not_active Withdrawn
- 2017-02-28 KR KR1020187027578A patent/KR20180118702A/ko not_active Ceased
- 2017-02-28 AU AU2017227967A patent/AU2017227967B2/en not_active Expired - Fee Related
- 2017-02-28 EA EA201891670A patent/EA201891670A1/ru unknown
- 2017-02-28 CN CN201780014493.6A patent/CN109152825A/zh active Pending
- 2017-02-28 CA CA3014848A patent/CA3014848A1/en active Pending
- 2017-02-28 SG SG10202110228Y patent/SG10202110228YA/en unknown
- 2017-02-28 EP EP21171324.3A patent/EP3915577A1/en active Pending
- 2017-02-28 CR CR20210033A patent/CR20210033A/es unknown
- 2017-02-28 MA MA043690A patent/MA43690A/fr unknown
- 2017-02-28 MX MX2018010167A patent/MX2018010167A/es unknown
- 2017-02-28 SG SG10202008107QA patent/SG10202008107QA/en unknown
- 2017-02-28 JP JP2018543337A patent/JP2019516663A/ja active Pending
- 2017-02-28 WO PCT/EP2017/054559 patent/WO2017148888A1/en not_active Ceased
- 2017-02-28 SG SG11201806951TA patent/SG11201806951TA/en unknown
- 2017-02-28 CR CR20210034A patent/CR20210034A/es unknown
- 2017-02-28 US US15/445,461 patent/US10400011B2/en active Active
- 2017-02-28 CR CR20210035A patent/CR20210035A/es unknown
- 2017-02-28 IL IL261266A patent/IL261266B2/en unknown
- 2017-03-01 TW TW106106638A patent/TWI641617B/zh not_active IP Right Cessation
-
2018
- 2018-08-22 CO CONC2018/0008763A patent/CO2018008763A2/es unknown
-
2021
- 2021-05-23 JP JP2021086571A patent/JP7201740B2/ja active Active
- 2021-06-22 AU AU2021204201A patent/AU2021204201B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017148888A1 (en) | 2017-09-08 |
| KR20180118702A (ko) | 2018-10-31 |
| SG11201806951TA (en) | 2018-09-27 |
| MX2018010167A (es) | 2018-11-29 |
| US10400011B2 (en) | 2019-09-03 |
| CN109152825A (zh) | 2019-01-04 |
| EP3915577A1 (en) | 2021-12-01 |
| JP2021129580A (ja) | 2021-09-09 |
| MA43690A (fr) | 2021-06-02 |
| CR20210033A (es) | 2021-02-10 |
| IL261266B1 (en) | 2023-06-01 |
| CR20210035A (es) | 2021-02-10 |
| GB201603568D0 (en) | 2016-04-13 |
| IL261266B2 (en) | 2023-10-01 |
| SG10202110228YA (en) | 2021-10-28 |
| CA3014848A1 (en) | 2017-09-08 |
| MA43090A1 (fr) | 2018-10-31 |
| AU2017227967A1 (en) | 2018-09-06 |
| AU2021204201A1 (en) | 2021-07-15 |
| SG10202008107QA (en) | 2020-09-29 |
| CR20210034A (es) | 2021-02-10 |
| TWI641617B (zh) | 2018-11-21 |
| TW201734039A (zh) | 2017-10-01 |
| AU2017227967B2 (en) | 2021-03-25 |
| EP3423085A1 (en) | 2019-01-09 |
| EA201891670A1 (ru) | 2019-02-28 |
| AU2021204201B2 (en) | 2023-04-13 |
| JP7201740B2 (ja) | 2023-01-10 |
| IL261266A (en) | 2018-10-31 |
| JP2019516663A (ja) | 2019-06-20 |
| US20170253633A1 (en) | 2017-09-07 |
| CR20180398A (es) | 2018-11-30 |
| CO2018008763A2 (es) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018016734A2 (pt) | peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres | |
| BR112018015793A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra nhl e de outros cânceres | |
| BR112017027459A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de ovário e outros cânceres | |
| BR112018001687A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de próstata e outros cânceres | |
| BR112018017022A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão de células não pequenas e outros cânceres | |
| BR112018009980A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de mama e outros cânceres | |
| BR112017028558A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer epitelial de ovário e outros cânceres | |
| BR112018008806A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia de diversos cânceres | |
| BR112017017289A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra diversos tumores | |
| BR112018003460A2 (pt) | peptídeos, combinações de peptídeos e suportes para emprego na imunoterapia de diversos cânceres | |
| BR112017027639A2 (pt) | epítopos celulares e combinações de epítopos celulares para emprego na imunoterapia de mieloma e outros cânceres | |
| BR112017019217A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pâncreas e outros cânceres | |
| BR112017017560A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pulmão, incluindo cpcnp e outros câncere | |
| BR112017019804A2 (pt) | peptídeos e combinações de peptídeos e arcabouços para uso na imunoterapia contra o carcinoma de células renais (ccr) e outros cânceres | |
| BR112017028363A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de esôfago e outros cânceres | |
| BR112018007206A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra leucemia linfocítica crônica (cll) e outros cânceres | |
| BR112019003513A2 (pt) | peptídeos e suportes para uso em imunoterapia de carcinoma de células escamosas de cabeça e pescoço e outros cânceres | |
| BR112018015545A2 (pt) | tratamentos de câncer do útero | |
| BR112017023362A2 (pt) | peptídeos e combinação de peptídeos e arcabouços dos mesmos para uso na imunoterapia contra o carcinoma colorretal (crc) e outros cânceres | |
| BR122020014377A8 (pt) | Peptídeo, anticorpo, receptor de célula t, aptâmero, ácido nucleico, célula hospedeira recombinante, método in vitro de produção de linfócitos t ativados, linfócito t ativado, composição farmacêutica, método de produção do peptídeo, uso de um número eficaz de células t ativadas, uso do peptídeo, kit e método in vitro de produção de uma vacina anticâncer personalizada | |
| BR112018068489A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia anticâncer | |
| BR112018073921A2 (pt) | peptídeos e combinações de peptídeos que servem como alvos e para uso na imunoterapia do câncer da vesícula biliar, do colangiocarcinoma e de outros cânceres | |
| CR20200515A (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer | |
| MX2020012777A (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer. | |
| BR112018070873A2 (pt) | imunoterapia contra melanoma e outros cânceres |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |